

Top line SOLARIO data presented at EBJIS

BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces that the top line data from the SOLARIO trial, funded by the European Bone & Joint Infection Society (EBJIS) and the National Institute for Health and Care Research (NIHR UK), are expected to be presented on the opening day of the 42nd Annual Meeting of EBJIS in Barcelona from September 26th to 28th.

The SOLARIO* trial involves 500 adult patients with orthopedic infections who are followed for one year. The study's objective is to assess whether patients treated surgically with local antibiotic-eluting bone defect fillers, such as CERAMENT® G and CERAMENT® V, achieve similar outcomes when receiving either a short-term course of systemic antibiotics (up to seven days) or the conventional long-term regimen (at least four weeks of systemic antibiotics).

If the shorter systemic antibiotic regimen, with local antibiotics, proves to be non-inferior, it could offer significant advantages, including reduced antibiotic treatment duration and costs, fewer side effects, improved patient compliance, enhanced antimicrobial stewardship, with a decreased risk of antibiotic resistance. The results are expected to be published during next year.

*Dudareva M, Kumin M, Vach W, Kaier K, Ferguson J, McNally M, Scarborough M. Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): a randomized controlled open-label non-inferiority trial of duration of systemic antibiotics in adults with orthopaedic infection treated operatively with local antibiotic therapy. *Trials* 2019; 20: 693.

For more information contact:

BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
05 September 2024 11:00:00 CEST



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[Top line SOLARIO data presented at EBJIS](#)